360 related articles for article (PubMed ID: 16091497)
1. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
Barbet J; Campion L; Kraeber-Bodéré F; Chatal JF;
J Clin Endocrinol Metab; 2005 Nov; 90(11):6077-84. PubMed ID: 16091497
[TBL] [Abstract][Full Text] [Related]
2. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis.
Meijer JA; le Cessie S; van den Hout WB; Kievit J; Schoones JW; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2010 Apr; 72(4):534-42. PubMed ID: 19563448
[TBL] [Abstract][Full Text] [Related]
3. Medullary thyroid carcinoma surgical cytoreduction induces an increase in serum calcitonin and carcinoembryonic antigen doubling times.
Papapetrou PD; Polymeris A
Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):164-8. PubMed ID: 22328112
[TBL] [Abstract][Full Text] [Related]
4. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
5. Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.
Karga H; Giagourta I; Papaioannou G; Doumouchtsis K; Polymeris A; Thanou S; Papamichael K; Zerva C
Metabolism; 2011 May; 60(5):604-8. PubMed ID: 20667564
[TBL] [Abstract][Full Text] [Related]
6. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
7. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.
Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E
Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698
[TBL] [Abstract][Full Text] [Related]
8. Medullary thyroid carcinoma with nodular goiter carries an excellent prognosis.
Xu L; Wang WB; Zhao YP; Zhang TP; Liao Q; Chen G; Zhou L; Shu H
J Surg Oncol; 2012 Aug; 106(2):169-73. PubMed ID: 22354558
[TBL] [Abstract][Full Text] [Related]
9. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
Kebebew E; Ituarte PH; Siperstein AE; Duh QY; Clark OH
Cancer; 2000 Mar; 88(5):1139-48. PubMed ID: 10699905
[TBL] [Abstract][Full Text] [Related]
10. Determinants of life expectancy in medullary thyroid cancer: age does not matter.
de Groot JW; Plukker JT; Wolffenbuttel BH; Wiggers T; Sluiter WJ; Links TP
Clin Endocrinol (Oxf); 2006 Dec; 65(6):729-36. PubMed ID: 17121523
[TBL] [Abstract][Full Text] [Related]
11. Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005.
Grozinsky-Glasberg S; Benbassat CA; Tsvetov G; Feinmesser R; Peretz H; Shimon I; Lapidot M
Thyroid; 2007 Jun; 17(6):549-56. PubMed ID: 17614776
[TBL] [Abstract][Full Text] [Related]
12. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy.
Kwon H; Kim WG; Jeon MJ; Song DE; Lee YM; Sung TY; Chung KW; Yoon JH; Hong SJ; Baek JH; Lee JH; Kim TY; Kim WB; Shong YK
Endocrine; 2016 Jul; 53(1):174-81. PubMed ID: 26754662
[TBL] [Abstract][Full Text] [Related]
13. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
Łacka K; Michałek K; Majewski P
Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
[TBL] [Abstract][Full Text] [Related]
14. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis.
Machens A; Ukkat J; Hauptmann S; Dralle H
Arch Surg; 2007 Mar; 142(3):289-93; discussion 294. PubMed ID: 17372055
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic values of the doubling time of serum carcinoembryonic antigen and calcitonin levels in medullary thyroid carcinoma].
Miyauchi A; Onishi T; Matsuzuka F; Hirai K; Kuma K; Takai S; Nakamoto K; Nakamura K; Nanjo S; Maeda M
Gan No Rinsho; 1986 Oct; 32(12):1519-24. PubMed ID: 3783976
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-based risk stratification for previously untreated medullary thyroid cancer.
Machens A; Dralle H
J Clin Endocrinol Metab; 2010 Jun; 95(6):2655-63. PubMed ID: 20339026
[TBL] [Abstract][Full Text] [Related]
17. Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma.
Siironen P; Hagström J; Mäenpää HO; Louhimo J; Arola J; Haglund C
Acta Oncol; 2016; 55(3):357-64. PubMed ID: 26339947
[TBL] [Abstract][Full Text] [Related]
18. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
[TBL] [Abstract][Full Text] [Related]
19. Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma?
Bümming P; Ahlman H; Nilsson B; Nilsson O; Wängberg B; Jansson S
Langenbecks Arch Surg; 2008 Sep; 393(5):699-703. PubMed ID: 18626656
[TBL] [Abstract][Full Text] [Related]
20. Medullary thyroid cancer with undetectable serum calcitonin.
Brutsaert EF; Gersten AJ; Tassler AB; Surks MI
J Clin Endocrinol Metab; 2015 Feb; 100(2):337-41. PubMed ID: 25490273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]